Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

15.18 -0.07 (-0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, NASDAQ:ADMA is worth considering. 
Via Chartmill
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation
From Kirby McInerney LLP
Via Business Wire
(ADMA) - Analyzing ADMA Biologics's Short Interest
 
Via Benzinga
Key Takeaways From ADMA Biologics Analyst Ratings
 
Via Benzinga
This Is What Whales Are Betting On ADMA Biologics
 
Via Benzinga
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)
From Kirby McInerney LLP
Via Business Wire
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
The company reiterated its outlook for 2024 and 2025. 
Via Investor's Business Daily
Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA).
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock. 
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA. 
Via Chartmill
Buckle Up And Use Volitility To Your Advantage
The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line is outright scary. 
Via Talk Markets
What You Missed On Wall Street This Past Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
 
Via Benzinga
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly. 
Via Investor's Business Daily
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
ADMA Biologics Set to Join S&P SmallCap 600 Index
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
What's Going On With ADMA Biologics Stock Monday?
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.